熱門資訊> 正文
诺和诺德向FDA提交血友病治疗申请审查
2025-09-29 21:33
- 諾和諾德(NVO) 0
- Frontier Acquisition Corp. Class A(FRON) 0
- T.Rowe Price International Equity Research ETF(TIER) 0
- Novo Nordisk (NVO) said that it has filed a biologic marketing application for Mim8 (denecimig) with the US FDA as a treatment to help prevent or lessen bleeding episodes in individuals with hemophilia A.
- The submission is based on findings from the FRONTIER study program, which was created to demonstrate the effectiveness and safety of denecimig.
More on Novo Nordisk
- Novo Nordisk: Wegovy Sales Soar, Trump Tariffs No Threat
- Novo Nordisk: Don't Be Deterred By Outlook Downgrades
- Novo Nordisk: Attractive Buying Opportunity In A Distracted Market
- Trump’s 100% drug tariffs send pharma stocks lower
- Novo Nordisk reduces its U.S. sales team for obesity and diabetes education: Reuters
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
